Jun 4, 2001|
US markets in an uncertain zone
It was a roller coaster week for the US markets. Earnings warnings from Sun Microsystems, Alcatel and EMC shook the confidence of the markets. On the other hand mixed outlook on the economy front and better than expected sales data from General Motors fueled the late rally in the markets.
Economic data showed some positive signs. The jobless rate eased to 4.4% in May from 4.5% in April. The consumer confidence index jumped to 115.5 in May from 109.9 in April. Spending on goods and services also grew at a faster pace of 0.4%, from 0.2% in March. However, personal income grew at a slower rate of 0.3% in April, down from 0.5% in March. These reports suggest that economic weakness has not severely dented consumer buying behaviour as spending has increased faster than income growth.
The negative news was from the National Association of Purchasing Management, which announced a fall in the manufacturing index to 42.1 in May from 43.2 in April. A reading below 50 signals contracting manufacturing activity, which comprises 20% of the U.S. economy. The mixed signals from the economy are probably leading to a cautious buying in the US markets.
Dr. Reddy outperforms
|(Price in $)
The pharma major Dr. Reddy’s was the only gainer among the Indian ADRs. The latest developments in the company generated a strong buying interest in the stock.
Dr. Reddy’s reported a 69% growth in revenues and over 12% growth in profits for FY01. The merger with Cheminor fueled the financial performance of the company. Among the latest developments, the company has licensed its third anti-diabetic molecule to Novartis AG. As per the agreement Novartis will get worldwide exclusive rights and in return Dr. Reddy’s may fetch up to US$ 55 million as upfront and milestone payments as well as royalties depending on the success of molecule. The company has also benefited from the US court’s ruling against Eli Lilly. Dr. Reddy’s would be the only company to market a generic form of Prozac capsule (Eli Lilly’s patent expires in 2003) through Pharmaceutical Resources Inc. during the exclusivity period. The brand has annual projected sales of US$ 250 m.
Among the tech ADRs, Satyam was the largest loser. The company plans to list its loss making Internet subsidiary Sify in the Indian markets by September ’01. It is also not sure of when its loss making subsidiaries will break even. This has put pressure on the stock price.
Wipro, which was down by 4.5% over a week managed to gain some points in the last two days. This was on news of its appointment by Ericsson as a preferred supplier for consultancy services within the field of R&D consulting.
US markets seems to be in an uncertain zone with weakening corporate earnings and bleak economic data. Some of the tech majors are expected to declare their results in the coming week, and their future outlook could partially decide the trend of the markets in short term.
NASDAQ shakes global markets
More Views on News
Jun 14, 2017
Should you subscribe to the IPO of Tejas Networks Ltd?
May 26, 2017
Don't be surprised to come across some Super Investors there!
May 19, 2017
Not all small-cap investors see themselves as traders. Some see themselves as business owners.
Jul 31, 2017
Should you subscribe to the IPO of Securities & Intelligence Services Ltd?
Jul 8, 2017
If Super Investors can wait for the right pitch, so can you.
More Views on News
Aug 17, 2017
A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.
Aug 21, 2017
Most Indians who cannot find jobs, look at becoming self-employed.
Aug 16, 2017
The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?
Aug 16, 2017
Ensure your financial Independence, and pledge to start the journey towards financial freedom today!
Aug 22, 2017
Post demonetisation, a cut in bank savings deposits rates was in the offing.
Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement. LEGAL DISCLAIMER:
Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here
. The performance data quoted represents past performance and does not guarantee future results.SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: email@example.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407